AIOM 2022 - XXIV National Congress of Italian Association of Medical Oncology
Nov 05 - Nov 07, 2022 | RomeItaly
LARVOL is not affiliated with XXIV National Congress of Italian Association of Medical Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 44 abstracts linked to Trials
DURABILITY OF EFFICACY WITH SELPERCATINIB IN PATIENTS (PTS) WITH RET FUSION+ NON-SMALL-CELL LUNG CANCER (NSCLC)
CABOZANTINIB (C) PLUS ATEZOLIZUMAB (A) AS A FIRST- OR SECOND-LINE THERAPY FOR PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) AND PREVIOUSLY-TREATED EGFR MUTANT ANSCLC
SARS-COV-2 OMICRON (B.1.1.529) VARIANT INFECTION LEADS TO HIGH MORBIDITY AND MORTALITY IN UNVACCINATED PATIENTS WITH CANCER
REAL-WORLD OUTCOMES OF PATIENTS WITH ADVANCED LUNG ADENOCARCINOMA TREATED WITH FIRSTLINE CHEMO-IMMUNOTHERAPY IN ITALY
OSIMERTINIB IN UNTREATED EGFRMUTANT NON-SMALL CELL LUNG CANCERS: OVERALL SURVIVAL AND BUDGET IMPACT ANALYSIS IN REAL-WORLD
OSIMERTINIB IN EGFR-MUTANT ADVANCED NSCLC: THE ATLAS MULTICENTRE COHORT STUDY
BUDGET IMPACT ANALYSIS OF CEMIPLIMAB FOR FIRST-LINE (1L) ADVANCED NONSMALL CELL LUNG CANCER (NSCLC) WITH PROGRAMMED CELL DEATH-LIGAND 1 (PDL1)= 50% IN ITALY
TRASTUZUMAB DERUXTECAN (T-DXD) IN HER2 POSITIVE (HER2+), ADVANCED BREAST CANCER (ABC): A SINGLE INSTITUTION, REAL WORLD EXPERIENCE
RISK OF DRUG-INDUCED INTERSTITIAL LUNG DISEASE IN PATIENTS WITH METASTATIC BREAST CANCER TREATED WITH ANTIHER2 REGIMENS: A NETWORK META-ANALYSIS
SAFETY OF RUCAPARIB AS MAINTENANCE THERAPY AFTER PLATINUM-BASED CHEMOTHERAPY IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: THE REALLIFE EXPERIENCE IN PUGLIA
AN OBSERVATIONAL, MONOCENTRIC, RETROSPECTIVE ANALYSIS OF MEN WITH NEW DIAGNOSIS OF HIGH-RISK METASTATIC CASTRATION NAÏVE PROSTATE CANCER FOLLOWING ABIRATERONE ACETATE PLUS PREDNISONE AND ANDROGEN DEPRIVATION THERAPY
PEMBROLIZUMAB AS SECOND LINE TREATMENT IN METASTATIC UROTHELIAL CANCER: A MULTICENTER REAL LIFE STUDY
SAFETY AND EFFICACY OUTCOMES IN HEAD AND NECK CANCER (HNC) PATIENTS (PTS) TREATED WITH FIRST-LINE (1L) PEMBROLIZUMAB (P), ALONE OR WITH CHEMOTHERAPY (CT)
PEMBROLIZUMAB ALONE OR WITH CHEMOTHERAPY FOR RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M HNSCC): A SINGLE INSTITUTIONAL RETROSPECTIVE REPORT
TUMOUR-AGNOSTIC INDICATIONS: ARE WE MOVING TOWARDS A MUTATION-DRIVEN APPROACH IN PRECISION ONCOLOGY?